Investment momentum GRAM has recently committed a $100 million investment to expand sterile manufacturing capabilities, including a new sterile-filling line and GMP facility, signaling strong capacity growth and potential for longer-term CDMO partnerships.

Leadership expansion Appointment and promotion of Denis Johnson to Chief Executive Officer in 2025 indicates strategic leadership focus and potential readiness to scale, appealing to clients seeking stable, growth-oriented manufacturing partners.

Strategic partnerships GRAM collaborates with drug-delivery device innovators, including a notable partnership with SHL Medical, highlighting opportunities to co-develop autoinjector and on-body delivery solutions for clients with device integration needs.

Clinical to commercial As a sterile injectable CDMO with end-to-end capabilities from fill-finish to packaging, GRAM offers a pathway for clients from clinical trials through commercialization, aligning with sponsors seeking scaled, compliant manufacturing.

Recognition and growth Industry awards for Best and Brightest Companies to Work For and Growth highlight strong employee engagement and a high-growth profile, which can be leveraged to attract talent-filled projects and reassure customers of operational stability.